Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 14/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11232475 | 0.80 | SIGMAR1 (0.54) | OPRM1SIGMAR1KCNH2 | |
| SCHEMBL11229423 | 0.80 | SIGMAR1 (0.55) | OPRM1SIGMAR1KCNH2 | |
| SCHEMBL20555604 | 0.75 | SIGMAR1 (0.56) | OPRM1SIGMAR1KCNH2 | |
| SCHEMBL17318950 | 0.75 | SIGMAR1 (0.62) | OPRM1SIGMAR1KCNH2 | |
| SCHEMBL18785069 | 0.75 | SIGMAR1 (0.50) | OPRM1SIGMAR1KCNH2 | |
| SCHEMBL18785461 | 0.75 | SIGMAR1 (0.50) | OPRM1SIGMAR1KCNH2 | |
| SCHEMBL18785457 | 0.75 | SIGMAR1 (0.50) | OPRM1SIGMAR1KCNH2 | |
| SCHEMBL18785077 | 0.75 | SIGMAR1 (0.50) | OPRM1SIGMAR1KCNH2 | |
| SCHEMBL4458414 | 0.72 | CHRNA7 (0.38) | OPRM1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL3041445 | 0.70 | CHRNA7 (0.37) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| EP-4129996-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-02-08 | — | — | EP | disclosed |
| US-4353901-A | HYPERTENSION, CONGESTIVE HEART FAILURE, ARRHYTHMIAMIGRAINE, VASOSPASTIC DISORDERS, ASTHMA | SYNTEX (U.S.A.) INC. (US) | 1982-10-12 | — | — | US | disclosed |
| US-4353900-A | HYPOTENSIVE, ANTIARRHYTHMIA, CARDIOTONIC, VASODILATORS | SYNTEX (U.S.A.) INC. (US) | 1982-10-12 | — | — | US | disclosed |
| EP-0061333-A1 | 9-(2-(3-Indolyl)ethyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones | SYNTEX (U.S.A.) INC. (US) | 1982-09-29 | — | — | EP | disclosed |
| US-4332804-A | TREATMENT OF HYPERTENSION, CONGESTIVE HEART FAILURE, ARRHYTHMIA, MIGRAINE, VASOSPASTIC DISORDERS AND ASTHMA | SYNTEX (U.S.A.) INC. (US) | 1982-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | OPRM1 3589/4885SIGMAR1 4407/4885KCNH2 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.